. 2019 Jun 18;10(40):4026–4037. doi: 10.18632/oncotarget.26999

Table 3. Shows KRAS/GNAS mutation prevalence across different cytology groups.

Molecular analysis	KRAS, n (%)	GNAS, n (%)	KRAS or GNAS, n (%)
Cytology diagnoses	KRAS, n (%)	GNAS, n (%)	KRAS or GNAS, n (%)
Non-diagnostic “ND”	32/87 (36.8%)	15/51 (29.4%)	38/87 (43.7%)
Negative “NEG”	32/154 (20.8%)	14/81 (17.3%)	36/154 (23.4%)^*
Atypical/suspicious “ATY/SUS”	43/51 (84.3%)	15/34 (44.1%)	44/51 (86.3%)
Positive “POS”	8/11 (72.7%)	3/9 (33.3%)	9/11 (81.8%)

Note: Patients with more than one mutation are represented in multiple categories.

(^*the presence of a gene mutation is significantly lower in the negative “NEG” group compared to other groups, see text for further details).